Rhythm Pharmaceuticals, Inc.
32
3
7
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 32 trials
100.0%
+13.5% vs industry average
31%
10 trials in Phase 3/4
59%
13 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (32)
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Role: lead
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Role: lead
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Role: lead
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Role: lead
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Role: lead
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Role: lead
Early Genetic Identification of Obesity
Role: collaborator
Open-Label Extension Study of Setmelanotide
Role: lead
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Role: lead
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Role: lead
Long Term Extension Trial of Setmelanotide
Role: lead
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Role: lead
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Role: lead
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Role: lead
INDIcators for Clarifying the bAckground of exTreme Obesity in childRen
Role: collaborator
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
Role: lead
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Role: lead
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Role: lead
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Role: lead
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
Role: lead